No-Reflow Phenomenon

No-reflow is responsible for 40% of the primary percutaneous coronary intervention without complete myocardial reperfusion despite successful reopening of the infarct-related artery. This review describes the main pathophysiological mechanisms of no-reflow, its clinical manifestation, including the strong association with increased in-hospital mortality, malignant arrhythmias, and cardiac failure as well as the diagnostic methods. The latter ranges from simple angiographic thrombolysis in myocardial infarction grade score to more complex angiographic indexes, imaging techniques such as myocardial contrast echo or cardiac magnetic resonance, and surrogate clinical end points such as ST-segment resolution. This review also summarizes the strategies of prevention and treatment of no-reflow, considering the most recent studies results regarding medical therapy and devices.

[1]  Harlan M Krumholz,et al.  Time to treatment in primary percutaneous coronary intervention. , 2007, The New England journal of medicine.

[2]  S. Sdringola,et al.  Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow‐no reflow phenomenon , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[3]  S. Germain,et al.  Protection against Myocardial Infarction and No-reflow through Preservation of Vascular Integrity by Angiopoietin-like 4 Running Title: Galaup Et Al.; Protecting Vascular Integrity in Heart Ischemia , 2022 .

[4]  G. Gross,et al.  Effects of nicorandil and glyceryl trinitrate on infarct size, adenosine release, and neutrophil infiltration in the dog. , 1995, Cardiovascular research.

[5]  H. Yip,et al.  Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. , 2002, Chest.

[6]  P. Jariwala.  Prospective, randomized, multicenter evaluation of a polyethylene terephthalate micronet mesh-covered stent (MGuard) in ST-segment elevation myocardial infarction: the MASTER trial. , 2013 .

[7]  L. Tavazzi,et al.  Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. , 2012, Atherosclerosis.

[8]  G. Montalescot,et al.  The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes , 2005, Diabetes & vascular disease research.

[9]  J. Maublant,et al.  Effect of thrombus aspiration on infarct size and left ventricular function in high-risk patients with acute myocardial infarction treated by percutaneous coronary intervention. Results of a prospective controlled pilot study. , 2009, American heart journal.

[10]  P. Marraccini,et al.  Primary coronary angioplasty in acute myocardial infarction: clinical correlates of the 'no reflow' phenomenon. , 1998, International journal of cardiology.

[11]  K. Eagle,et al.  Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events , 2006, Heart.

[12]  W. Laskey,et al.  Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features. , 1990, Circulation.

[13]  R. Kloner,et al.  No-reflow phenomenon. , 2002, Circulation.

[14]  H. Suryapranata,et al.  Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. , 2012, Atherosclerosis.

[15]  M. Fujii,et al.  Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction , 2004, Heart.

[16]  H. Suryapranata,et al.  A meta-analytic overview of thrombectomy during primary angioplasty. , 2013, International journal of cardiology.

[17]  M. Klapholz,et al.  Coronary stenting with MGuard: from conception to human trials. , 2008, Cardiovascular revascularization medicine : including molecular interventions.

[18]  S. Sdringola,et al.  Risk assessment of slow or no‐reflow phenomenon in aortocoronary vein graft percutaneous intervention , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[19]  L. Ohno-Machado,et al.  No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. , 2003, American heart journal.

[20]  A. Dart,et al.  Management of the no-reflow phenomenon. , 2011, Pharmacology & therapeutics.

[21]  W. O’Neill,et al.  Features and outcome of no-reflow after percutaneous coronary intervention. , 1995, The American journal of cardiology.

[22]  G. Niccoli,et al.  No-reflow: again prevention is better than treatment. , 2010, European heart journal.

[23]  G. Finet,et al.  Postconditioning the Human Heart , 2005, Circulation.

[24]  H. Suryapranata,et al.  Stenting and abciximab in primary angioplasty: a review of current status. , 2005, Italian heart journal : official journal of the Italian Federation of Cardiology.

[25]  C. Indolfi,et al.  Direct coronary stenting: Effect on coronary blood flow, immediate and late clinical results , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[26]  R. Kloner,et al.  The “no-reflow” phenomenon: basic science and clinical correlates , 2002, Heart.

[27]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .

[28]  H. Sarau,et al.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 , 1999, Nature.

[29]  M. Chiariello,et al.  Is direct stenting superior to stenting with predilation in patients treated with percutaneous coronary intervention? results from a meta-analysis of 24 randomised controlled trials , 2010, Heart.

[30]  H. Oflaz,et al.  Association of haematological indices with the degree of microvascular injury in patients with acute anterior wall myocardial infarction treated with primary percutaneous coronary intervention , 2006, Heart.

[31]  Katherine C. Wu,et al.  Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. , 1998, Journal of the American College of Cardiology.

[32]  F. Zijlstra,et al.  Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study , 2008, The Lancet.

[33]  R. Gao,et al.  Pretreatment with simvastatin reduces myocardial no‐reflow by opening mitochondrial KATP channel , 2006, British journal of pharmacology.

[34]  F. Burzotta,et al.  Myocardial no-reflow in humans. , 2009, Journal of the American College of Cardiology.

[35]  M. Hori,et al.  Distal Protection Improved Reperfusion and Reduced Left Ventricular Dysfunction in Patients With Acute Myocardial Infarction Who Had Angioscopically Defined Ruptured Plaque , 2005, Circulation.

[36]  A. Zanchetti,et al.  Postischemic left ventricular dysfunction is abolished by alpha-adrenergic blocking agents. , 1998, Journal of the American College of Cardiology.

[37]  J. A. Sloane,et al.  Cardiac-derived thromboxane A2. An initiating mediator of reperfusion injury? , 1993, The Journal of thoracic and cardiovascular surgery.

[38]  D. Berman,et al.  Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. , 2006, Journal of the American College of Cardiology.

[39]  J. Boura,et al.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials , 2022 .

[40]  G. Montalescot,et al.  Systematic primary aspiration in acute myocardial percutaneous intervention: a multicentre randomised controlled trial of the export aspiration catheter. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[41]  A. DeMaria,et al.  Ischemia-Reperfusion Injury at the Microvascular Level: Treatment by Endothelin A–Selective Antagonist and Evaluation by Myocardial Contrast Echocardiography , 2000, Circulation.

[42]  D. Baim,et al.  Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. , 1994, Circulation.

[43]  F. Neumann,et al.  Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. The JETSTENT trial. , 2010, Journal of the American College of Cardiology.

[44]  L. Galiuto.  Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenetic classification , 2004, Heart.

[45]  R. Califf,et al.  Myocardial Infarction Adenosine as an Adjunct to Thrombolytic Therapy for Acute Myocardial Infarction , 1999 .

[46]  G. Parodi,et al.  Comparison of rheolytic thrombectomy before direct infarct artery stenting versus direct stenting alone in patients undergoing percutaneous coronary intervention for acute myocardial infarction. , 2004, The American journal of cardiology.

[47]  D. Leosco,et al.  Rheolytic thrombectomy during percutaneous coronary intervention improves long-term outcome in high-risk patients with acute myocardial infarction. , 2007, Journal of interventional cardiology.

[48]  Koichi Inoue,et al.  Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. , 2006, European heart journal.

[49]  N. Uriel,et al.  Coronary stenting with MGuard: extended follow-up of first human trial. , 2011, Cardiovascular revascularization medicine : including molecular interventions.

[50]  F. Fedele,et al.  Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. , 2009, Journal of the American College of Cardiology.

[51]  E. Capati,et al.  Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional Recovery and Remodeling After Primary Angioplasty , 2009, Circulation. Cardiovascular interventions.

[52]  T. Carew,et al.  The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion. , 1987, Circulation.

[53]  F. Fedele,et al.  The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: results of the multicenter AMICI study. , 2008, Journal of the American College of Cardiology.

[54]  J. Stamler,et al.  Antiplatelet Effects of a Novel Antianginal Agent, Nicorandil , 1994, Journal of cardiovascular pharmacology.

[55]  S. Dixon,et al.  Embolic protection of saphenous vein graft percutaneous interventions. , 2007, Journal of interventional cardiology.

[56]  M. Ishihara,et al.  Effects of various doses of intracoronary diltiazem on coronary resistance vessels in humans. , 1995, Japanese circulation journal.

[57]  G. Stone,et al.  Saphenous vein graft intervention. , 2011, JACC: Cardiovascular Interventions.

[58]  K. Okumura,et al.  Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. , 2000, Journal of the American College of Cardiology.

[59]  C. Hung,et al.  Time‐dependent benefit of initial thrombosuction on myocardial reperfusion in primary percutaneous coronary intervention , 2007, International journal of clinical practice.

[60]  R. Guyton,et al.  Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. , 2003, American journal of physiology. Heart and circulatory physiology.

[61]  R. Kloner,et al.  Coronary no‐reflow phenomenon: From the experimental laboratory to the cardiac catheterization laboratory , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[62]  H. Ishizaka,et al.  Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. , 2004, American heart journal.

[63]  E. Vicaut,et al.  Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. , 2007, European heart journal.

[64]  D. Leosco,et al.  Multicentre experience with MGuard™ net protective stent in ST‐elevation myocardial infarction: Safety, feasibility, and impact on myocardial reperfusion , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[65]  E. Topol,et al.  Recognition of the importance of embolization in atherosclerotic vascular disease. , 2000, Circulation.

[66]  T Akasaka,et al.  Relation of phasic coronary flow velocity characteristics with TIMI perfusion grade and myocardial recovery after primary percutaneous transluminal coronary angioplasty and rescue stenting. , 2000, Circulation.

[67]  G. Amit,et al.  Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. , 2006, American heart journal.

[68]  G. Stone,et al.  Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a meta-analysis of randomized trials. , 2007, American heart journal.

[69]  E. Antman,et al.  Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. , 2005, JAMA.

[70]  T. Murohara,et al.  Impact of a Single Intravenous Administration of Nicorandil Before Reperfusion in Patients With ST-Segment–Elevation Myocardial Infarction , 2005, Circulation.

[71]  C. Liu,et al.  Suppression of NF-κB Reduces Myocardial No-Reflow , 2012, PloS one.

[72]  R. de Caterina,et al.  EMERALD, AIMI, and PROMISE: is there still a potential for embolic protection in primary PCI? , 2006, European heart journal.

[73]  M. Hori,et al.  Progressive decreases in coronary vein flow during reperfusion in acute myocardial infarction: clinical documentation of the no reflow phenomenon after successful thrombolysis. , 1994, Journal of the American College of Cardiology.

[74]  F. Piscione,et al.  MGUard versus bAre‐metal stents plus manual thRombectomy in ST‐elevation myocarDial infarction pAtieNts—(GUARDIAN) trial: Study design and rationale , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[75]  R. Kloner,et al.  The "no-reflow" phenomenon after temporary coronary occlusion in the dog. , 1974, The Journal of clinical investigation.

[76]  M. Ishihara,et al.  Effects of various doses of intracoronary verapamil on coronary resistance vessels in humans. , 1997, Japanese circulation journal.

[77]  M. Hori,et al.  Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. , 1996, Circulation.

[78]  K. Schindler,et al.  Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarct , 2008, Circulation.

[79]  F. Burzotta,et al.  Filter no reflow during percutaneous coronary interventions using the Filterwire distal protection device. , 2004, International journal of cardiology.

[80]  R. Gibbons,et al.  A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). , 2005, Journal of the American College of Cardiology.

[81]  M. Schocke,et al.  Prognostic value at 5 years of microvascular obstruction after acute myocardial infarction assessed by cardiovascular magnetic resonance , 2012, Journal of Cardiovascular Magnetic Resonance.

[82]  A. Groothuis,et al.  Coronary stenting with M-Guard: feasibility and safety porcine trial. , 2007, The Journal of invasive cardiology.

[83]  Neville Kukreja,et al.  Use of thrombectomy devices in primary percutaneous coronary intervention: a systematic review and meta-analysis. , 2013, International journal of cardiology.

[84]  C. Cannon,et al.  Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? , 1995, Circulation.

[85]  G. Maurer,et al.  Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. , 2002, Blood.

[86]  H. Hellstrom.  Coronary artery stasis after induced myocardial infarction in the dog. , 1971, Cardiovascular research.

[87]  Pierre Croisille,et al.  Effect of cyclosporine on reperfusion injury in acute myocardial infarction. , 2008, The New England journal of medicine.